Past editions

Today's AI: the world · 2026-10-22

Leadership in drug discovery and penetration of AI into humans

Published every day at 06:00 local time (Etc/UTC)

AI around the world

Leadership in drug discovery and penetration of AI into humans

OpenAI's acquisition of Orchestra Bio, Astellas' $400 million deal with AI Proteins, Qualcomm's layoffs and pivot to AI data centers. A series of reports over the past half day indicate that AI is deciding where funds go for research, equipment, and staffing. Meanwhile, in an article listing Americans' fears, anxiety about AI ranked in the top 10, and Duke University is progressing with the clinical implementation of AI for dementia. This sequence cannot be explained solely by measuring how accurate the technology has become. The success or failure of AI implementation now depends on how organizations position AI and how people perceive it. In each of the following sections, we will examine these changes based on individual reports.

OpenAI has acquired AI drug discovery startup Orchestra Bio. CHOSUNBIZ reported on the acquisition as a move to "accelerate AI-driven drug discovery," and another article headlined accelerating new drug development. Business+IT reports that the acquisition comes amid increasing competition from Anthropic and Google. AI companies chose to acquire startups rather than conduct their own R&D as a way to enter drug discovery. When evaluating AI for drug discovery, it is no longer sufficient to simply compare model performance. Which companies have a strong drug discovery team and technology on hand will also factor into the decision.

Full world overview →

Every item links to its original source. The regional analysis uses only the headlines listed on this page. The world part is taken from our AI Highlights.